The Ex Vivo Production of IL-6 and IL-21 by CD4+ T Cells is Directly Associated with Neurological Disability in Neuromyelitis Optica Patients
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Neuromyelitis optica (NMO), also known as Devic's disease, is an autoimmune, inflammatory disorder of the central nervous system (CNS) in which the immune system attacks myelin of the neurons located at the optic nerves and spinal cord, thus producing a simultaneous or sequential optic neuritis and myelitis. The objective of this study was evaluated the background T-cell function of patients suffering from neuromyelitis optica (NMO), an autoimmune disorder of the central nervous system. In our study, the in vitro T cell proliferation and the production of Th1 cytokines were significantly lower in cell cultures from NMO patients, as compared with healthy individuals. In contrast, a dominant Th17-like phenotype, associate with higher IL-23 and IL-6 production by LPS-activated monocytes, was observed among NMO patients. The release of IL-21 and IL-6 by polyclonally activated CD4+ T cells was directly correlated to neurological disability. In addition, the in vitro release of IL-21, IL-6 and IL-17 was significantly more resistant to glucocorticoid inhibition in NMO patients. In conclusion, the results indicate dominant Th17-related response in NMO patients that was directly proportional to neurological disability. Furthermore, our results can help to explain why NMO patients trend to be more refractory to corticoid treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies in AIDs, including NMOSD, mainly identify T cells with pro-inflammatory or B cell helper function. 16,24-31”
From Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases (2024) · cites this paper as [25]
In the citing paper
“Auto-Th cells with a pro-inflammatory or B cell helper profile are seen in AID patients, 16,24-31 but comprehensive ex vivo analyses are missing.”
From Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases (2024) · cites this paper as [25]
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Vignali, D. A. A., Collison, L. W., & Workman, C. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2343 · Cited by 3,463
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., & Weinshenker, B. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17551-x · Cited by 3,239
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,574
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S., & Hinson, S. R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050304 · Cited by 2,288
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,179
The clinical course of neuromyelitis optica (Devic’s syndrome)
Wingerchuk, D. M., Hogancamp, W. F., O’Brien, P. C., & Weinshenker, B. G. (1999) · Neurology · doi:10.1212/wnl.53.5.1107 · Cited by 1,822
Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression
Shevach, E. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.010 · Cited by 1,754
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica
Lucchinetti, C. F. (2002) · Brain · doi:10.1093/brain/awf151 · Cited by 1,210
Jovanović, D., Battista, J. A. D., Pelletier, J., Jolicoeur, F. C., He, Y., Zhang, M., Mineau, F., & Martel‐Pelletier, J. (1998) · PubMed · Cited by 973
Research works printed but not linked: 3
- Devic E. Myélite aiguë dorse-lombaire de névrite optique, autopsie. Congress Français de méd. Premiere Seance. 1984;9:434–9.
- Wingerchuk DM, Hogancamp WF, O’brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999;53:1107–14. · DOI · Paper page
- Matsuya N, Komori M, Nomura K, Nakane S, Fukudome T, Goto H, Shiraishi H, Wandinger KP, Matsuo H, Kondo T. Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica. Int Immunol. 2011;23(9):565–73. · DOI · Paper page
Cited by
Neuromyelitis optica: clinical features, immunopathogenesis and treatment
Jarius, S., Wildemann, B., & Paul, F. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12271 · Cited by 342
Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies
Carnero Contentti, E., & Correale, J. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02249-1 · Cited by 338
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies
Papadopoulos, M. C., Bennett, J. L., & Verkman, A. S. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.141 · Cited by 262
Glucocorticoids in T cell development, differentiation and function
Taves, M. D., & Ashwell, J. D. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00464-0 · Cited by 225
Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models
Wu, Y., Zhong, L., & Geng, J. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.12.002 · Cited by 160
Metadata
- Authors
- Linhares, U. C., Schiavoni, P. B., Barros, P. O., Kasahara, T. M., Teixeira, B., Ferreira, T. B., Alvarenga, R., Hygino, J., Vieira, M. M. M., Bittencourt, V. C. B., Andrade, R. M., Andrade, A. F., & Bento, C. A. M.
- Affiliations
- Universidade Federal do Estado do Rio de Janeiro (BR)
- Universidade do Estado do Rio de Janeiro (BR)
- Corresponding author
- Bento, Cleonice A. M.
- ORCID
- Venue
- Journal of Clinical Immunology
- Published
- 2012-09-05
- Volume
- 33
- Issue
- 1
- Pages
- 179-189
- ISSN
- 0271-9142 (ISSN-L)
- 1573-2592
- OpenAlex
- W1993219034
- Cited by
- 78
- References
- 57
- Citations by year
- 2025: 4 · 2024: 10 · 2023: 3 · 2022: 1 · 2021: 9 · 2020: 8 · 2019: 3 · 2018: 4 · 2017: 5 · 2016: 9 · 2015: 7 · 2014: 6 · 2013: 8
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Clinical Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neuromyelitis optica, CD4+ T cells, interleukin-6, IL-21, IL-17, Th17 cells, Th1 cytokines, neurological deficit, glucocorticoid resistance, T cell proliferation, IL-23, optic neuritis, myelitis, autoimmune central nervous system disease
- MeSH terms
- Interleukin-21, Adult, Cells, Cultured, Female, Humans, Interleukins, Lymphocyte Activation, Male, Middle Aged, Neuromyelitis Optica, CD4-Positive T-Lymphocytes, Interleukin-6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Ex Vivo Production of IL-6 and IL-21 by CD4+ T Cells is Directly Associated with Neurological Disability in Neuromyelitis Optica Patients. https://app.cochat.ai/papers/10.1007/s10875-012-9780-2
- The paper
- Linhares, U. C., Schiavoni, P. B., Barros, P. O., Kasahara, T. M., Teixeira, B., Ferreira, T. B., Alvarenga, R., Hygino, J., Vieira, M. M. M., Bittencourt, V. C. B., Andrade, R. M., Andrade, A. F., & Bento, C. A. M. (2013). The Ex Vivo Production of IL-6 and IL-21 by CD4+ T Cells is Directly Associated with Neurological Disability in Neuromyelitis Optica Patients. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-012-9780-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.